Elevance Health (ELV) stock price decline despite a Q2 beat and upwardly revised full-year adjusted EPS guidance is primarily due to Medicaid utilization pressure among the continuing member base, RBC Capital Markets said in a research report emailed Thursday.

Planned market exits over the next 18 months could also be cooling expectations around Medicaid recovery momentum, according to the note.

The company's Q2 outperformance was partly driven by Medicare Advantage, alongside an $0.80 per share net benefit related to investment portfolio valuation adjustments, which it will redeploy into accelerated investments in H2, analysts wrote.

The brokerage said it reiterated its sector perform rating on the stock and cut its price target to $424 per share from $439.

Price: 376.68, Change: -13.66, Percent Change: -3.50